<qa>  What type of DMARD should be started in patients responding insufficiently to MTXIn patients responding insufficiently to MTX andor other synthetic DMARDs with or without GCs, biological DMARDs should be started 1; current practice would be to start a TNF inhibitor adalimumab, certolizumab, etanercept, golimumab or infliximab which should be combined with MTX. 